IBA and ABX Announce the Successful Synthesis of 18F-PSMA-1007 on Synthera® Platform.

Many studies have demonstrated the clinical utility of the PSMA (Prostate Specific Membrane Antigen) ligands labeled 18F for prostate cancer imaging
Dresden, Germany, May 16th 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for diagnosis & treatment of cancer and ABX (Advanced Biochemical Compounds GmbH), the world’s leading provider of PET chemicals, announce today the implementation of 18F-PSMA-1007 on Synthera® platform. This achievement is the result of a collaboration between IBA and ABX and capitalizes on ABX’s expertise in the development of new radiopharmaceuticals and IBA Synthera® multi-tracer platform.
PSMA is a recognized target for prostate cancer.  According to the American Cancer society, About 1 man in 7 will be diagnosed with prostate cancer during his lifetime. There have been numerous studies based on low-molecular-weight agents with PSMA labelled with different radioisotopes. Initial studies with the second generation of 18F-labelled-PSMA-1007  for imaging of prostate cancer patients have demonstrated  its ability to reveal metastatic lesions that are difficult to be identified with other imaging modalities(1).
Neva Lazarova, Head of radiochemistry Solutions at IBA RadioPharma Solutions, commented:The development of the synthesis protocols for both 18F-PSMA on Synthera® V2 have been achieved with high yields and high radiochemical and chemical purity over its entire shelf-life. The recipes are soon available at the IBA Library of compounds and the set of consumables ready to use will be manufactured by ABX in Q2/Q3 2017. The processes will be soon available also on the new Synthera®+ generation.”
IBA RadioPharma Solutions will be showcasing the new Synthera®+ family at booth #23 during the ISRS congress. For more information about IBA’s new Synthera®+, see: iba-synthera.com
(1) The radiopharmaceuticals cited here are investigational drugs and can only be used under approved clinical trials application.
ABX is active in manufacturing and development of chemicals for nuclear medicine.
Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and
radiopharmaceutical distribution centers with their in-house radioisotopes production by providing
them global solutions, from project design to the operation of their facility.
In addition to high-quality technology production equipment, IBA has developed in-depth experience
in setting up GMP radiopharmaceuticals production centers
Synthera®+ is a multi-purpose automated synthesizer capable to produce 18F-FDG and other compounds (18FCH, 18FDOPA18FLT, Na18F,68Ga peptides …). This, smallest available module on the market, is designed to accommodate a wide range of radiochemistry processes.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
For further information please contact:
Rebecca Lo bue
Marketing director
Tel : +32 10 20 12 75